The analysis results showed that in the tissue samples of ovarian cancer patients resistant to PARP inhibitors, 8.7% (10/114) showed "High" expression of RORα, 21.0% (24/114) showed "Moderate" expression, 36.6% (36/114) showed "Weak" expression, and 38.6% (44/114) showed "Negative" expression. This evidence concerns the gene RORA and ovarian cancer.